The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.
The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.
复制标题
DOI：
10.3390/ph14030215
复制
发表时间：
2021-03-04
期刊：
影响因子：
--
通讯作者：
Siok Yee C
中科院分区：
文献类型：
--
作者：
Abou Assi R;Abdulbaqi IM;Siok Yee C
目前的研究表明，下一个无声的流行病将与慢性肝脏疾病有关，特别是非酒精性脂肪肝（NAFLD），该疾病于2020年更名为代谢相关脂肪肝（MAFLD）。在全球范围内，MAFLD死亡率正在上升。MAFLD的病因是多因素的，并且仍然不完全了解，但包括肝内脂质的积累、能量代谢的改变、胰岛素抵抗和炎症过程。因此，可用的MAFLD治疗依赖于改善患者的生活方式和多学科药物治疗选择，而手术选择在不管理MAFLD的合并症的情况下是无用的。纳米技术是解决MAFLD的新兴方法，其中纳米制剂被建议用于改善常规药物/草药的安全性和物理化学性质，物理，化学和生理稳定性以及肝脏靶向性质。构建了各种各样的肝脏纳米系统并将其递送至肝脏，在本综述中仅讨论了那些解决MAFLD的纳米载体类别、粒径、形状、zeta电位和提供的溶出速率、合适的制备方法、赋形剂（具有协同效应）以及用于装载的合适药物/化合物。还强调了每种纳米载体的优势和挑战，以及对MAFLD纳米药物生产中潜在前景的关注。
Current research indicates that the next silent epidemic will be linked to chronic liver diseases, specifically non-alcoholic fatty liver disease (NAFLD), which was renamed as metabolic-associated fatty liver disease (MAFLD) in 2020. Globally, MAFLD mortality is on the rise. The etiology of MAFLD is multifactorial and still incompletely understood, but includes the accumulation of intrahepatic lipids, alterations in energy metabolism, insulin resistance, and inflammatory processes. The available MAFLD treatment, therefore, relies on improving the patient’s lifestyle and multidisciplinary pharmacotherapeutic options, whereas the option of surgery is useless without managing the comorbidities of the MAFLD. Nanotechnology is an emerging approach addressing MAFLD, where nanoformulations are suggested to improve the safety and physicochemical properties of conventional drugs/herbal medicines, physical, chemical, and physiological stability, and liver-targeting properties. A wide variety of liver nanosystems were constructed and delivered to the liver, only those that addressed the MAFLD were discussed in this review in terms of the nanocarrier classes, particle size, shape, zeta potential and offered dissolution rate(s), the suitable preparation method(s), excipients (with synergistic effects), and the suitable drug/compound for loading. The advantages and challenges of each nanocarrier and the focus on potential promising perspectives in the production of MAFLD nanomedicine were also highlighted.
登录
查看更多内容
影响因子：
5.4
作者：
Abou Assi R;M Abdulbaqi I;Seok Ming T;Siok Yee C;A Wahab H;Asif SM;Darwis Y
通讯作者：
Darwis Y
影响因子：
3.8
作者：
Ballestri S;Nascimbeni F;Baldelli E;Marrazzo A;Romagnoli D;Lonardo A
通讯作者：
Lonardo A
影响因子：
5.3
作者：
Amaro-Gahete, Juan;Benitez, Almudena;Romero-Salguero, Francisco J.
通讯作者：
Romero-Salguero, Francisco J.
影响因子：
4.6
作者：
Alonso, Leocadio;Fox, Patrick F.;Fontecha, Javier
通讯作者：
Fontecha, Javier
影响因子：
--
作者：
Akbarzadeh A;Rezaei-Sadabady R;Davaran S;Joo SW;Zarghami N;Hanifehpour Y;Samiei M;Kouhi M;Nejati-Koshki K
通讯作者：
Nejati-Koshki K